Danaher
DHR
218.49
+2.88
+1.34%
Danaher
US · DHR
#143 by market cap
Listed 1970
218.49
+2.88
+1.34%
Live - 5344 symbols - heartbeat 259s ago
· 2026-10-08 09:15
Pre-market
218.05
-0.20%
After-hours
218.49
0.00%
Overnight
218.50
+0.00%
- Market cap
- 153.60B
- P/E (TTM)i
- 38.81
- P/Bi
- 2.92
- EPSi
- 5.05
- Div yieldi
- 0.66%
- 52W posi
- 72%
Reader sentiment
Are you bullish or bearish on DHR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 13 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 84.02% -0.09pp
- Institutions
- 2,512 -13
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund69.19%
Individual/Insider10.86%
Hedge Fund4.28%
Public Company3.77%
Private Company1.94%
Government Pension Fund1.79%
Sovereign Wealth Fund1.42%
Family Office/Trust0.69%
Insurance Company0.29%
Other5.77%
Top holders as of 2026-06-30
BlackRock
7.84% · 55.08M sh
Vanguard Capital Management, LLC
6.39% · 44.92M sh
Steven Rales
6.01% · 42.24M sh
Mitchell Rales
4.80% · 33.77M sh
State Street Global Advisors
4.05% · 28.46M sh
Other
70.91%
Capital Research
3.82% · 26.87M sh
FMR
3.78% · 26.54M sh
T. Rowe Price Group, Inc.
2.61% · 18.37M sh
Wellington Management Group
2.32% · 16.32M sh
Geode Capital Management, LLC
2.03% · 14.28M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 6 sells
| Name | Role | Stake |
|---|---|---|
| Steven Rales | Chairperson | 6.01% |
| Mitchell Rales | Co-Founder | 4.80% |
| Alan Spoon | Independent Director | 0.01% |
| John Schwieters | Independent Director | 0.01% |
| Rainer Blair | Chief Executive Officer | 0.01% |
| Matthew McGrew | Chief Financial Officer | 0.00% |
| Linda Filler | Lead Independent Director | 0.00% |
| Elias Zerhouni | Independent Director | 0.00% |
| Brian Ellis | Senior VP, General Counsel & Chief Compliance Officer | 0.00% |
| Daniel Raskas | Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Shashanka Muppaneni | Chief Strategy Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-30 | Heathre Moler | Senior VP & CHRO | Initial Statement of Beneficial | 0 | -- |
| 2026-08-20 | Rainer Blair | Chief Executive Officer | Open Market Disposition | -58,255 | $217.77–219.35 |
| 2026-08-03 | Steven Rales | Chairperson | Other Acquisition | +500,000 | -- |
| 2026-08-03 | Steven Rales | Chairperson | Other Derivative Acquisition | +1,000,000 | $194.78 |
| 2026-08-03 | Mitchell Rales | Co-Founder | Other Acquisition | +500,000 | -- |
| 2026-08-03 | Mitchell Rales | Co-Founder | Other Derivative Acquisition | +1,000,000 | $194.78 |
| 2026-08-03 | Gregory Milosevich | Executive Vice President of Life Sciences Business | Other Acquisition | +15,402 | -- |
| 2026-08-03 | Jose-Carlos Gutierrez-Ramos | Senior VP & Chief Science Officer | Other Acquisition | +13,477 | -- |
| 2026-08-03 | Matthew Gugino | Former VP of Investor Relations and FP&A | Other Derivative Acquisition | +153,563 | $194.78 |
| 2026-08-03 | Jonathan Leiken | General Counsel | Other Derivative Acquisition | +92,138 | $194.78 |
| 2026-08-03 | Christopher Riley | Executive VP of Biotechnology Group & CEO of Cytiva | Other Acquisition | +41,072 | -- |
| 2026-08-03 | Christopher Bouda | Vice President | Other Derivative Acquisition | +12,286 | $194.78 |
| 2026-08-03 | Julie Montgomery | Executive Vice President of Diagnostics | Other Derivative Acquisition | +245,701 | $194.78 |
| 2026-07-30 | Alan Spoon | Independent Director | Other Derivative Acquisition | +229 | -- |
| 2026-07-30 | Elias Zerhouni | Independent Director | Other Derivative Acquisition | +236 | -- |
| 2026-07-30 | Raymond Stevens | Independent Director | Other Derivative Acquisition | +181 | -- |
| 2026-07-30 | Linda Filler | Lead Independent Director | Other Derivative Acquisition | +18 | -- |
| 2026-07-30 | Teri List-Stoll | Independent Director | Other Derivative Acquisition | +15 | -- |
| 2026-07-30 | A. Sanders | Independent Director | Other Derivative Acquisition | +211 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:15:12 · For reference only, not investment advice and not tailored to your situation.